Codelivery of Raloxifene and Rutin as PEGylated Nanoliposomes: Formulation, Characterization, and Prophylactic...

Area of Science:

• Nanomedicine
• Drug Delivery
• Oncology

Background:

• Breast cancer remains a leading cause of cancer-related deaths in women.
• Conventional chemotherapy faces challenges including systemic toxicity and multidrug resistance.
• Nanotechnology offers potential for developing safer and more effective cancer therapies.

Purpose of the Study:

• To synthesize and characterize PEGylated nanoliposomes (NLs) loaded with raloxifene (RLX) and a combination of RLX and rutin.
• To evaluate the in vitro anti-cancer effects and safety profile of these nanoliposomes.

Main Methods:

• Thin-film hydration method for nanoliposome synthesis.
• Characterization using Zetasizer, TEM, and HPLC.
• Cell viability assays (MTT) on breast cancer and normal endothelial cell lines.

Main Results:

• High encapsulation efficiency achieved for RLX (91.28%) and rutin (78.12%) in mixed NLs.
• Nanoliposomes demonstrated stability for up to two months.
• Biphasic drug release observed, with reduced cytotoxicity against cancer cells and improved safety in normal cells.

Conclusions:

• PEGylated NLs loaded with RLX and rutin exhibit safe anti-breast cancer effects.
• The formulation shows potential for targeted and safer cancer treatment compared to mixed NLs.
• Further research is warranted for clinical translation.